WEDNESDAY, Sept. 25, 2024 (HealthDay News) — During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company’s high prices for its blockbuster drugs Ozempic and Wegovy. While testifying before the Senate Committee on Health, Education, Labor and Pensions,Continue Reading

MONDAY, Sept. 16, 2024 (HealthDay News) — Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that. In a new decades-long study, veterans with diabetes and what’s known as metabolic dysfunction-associated steatotic liverContinue Reading

THURSDAY, Sept. 12, 2024 (HealthDay News) — Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new clinical trial shows. The drugs’ active ingredient, semaglutide, reduced heart health risk by 20% in heavyset people who took it forContinue Reading

WEDNESDAY, Sept. 11, 2024 (HealthDay News) — The weight-loss drug liraglutide helped obese children lower their BMI and reach a healthier weight, researchers report. The findings, published Tuesday in the New England Journal of Medicine and presented simultaneously at the European Association for the Study of Diabetes annual meeting in Madrid,Continue Reading